Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKG0106 intravitreal injection in neovascular age-related macular degeneration (nAMD)
CTR20234110Phase 2Active
- Sponsor
- Lanyue Bio
- Start
- Apr 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SKG0106 in exudative macular degeneration, sponsored by Lanyue Bio. Primary endpoints: Incidence and characteristics of dose-limiting toxicities (DLTs) and Type, severity, and incidence of ocular and systemic adverse events. Started Apr 2024; status: active.
02
Drugs
SKG0106
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20234110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234110.